FACULTY

Estimated time to complete activity: 2.0 hours
Release Date: June 9, 2009
Expiration Date: June 8, 2010
This activity may be accessed at www.educationalconcepts.net.

FEATURED LECTURES

This activity is sponsored by

This activity is supported by educational grants from

Recently, incredible strides have been made in the treatment of hematologic malignancies posing a challenge to the clinician who must stay abreast of the most recent advances in therapy. One of the most widely studied approaches to the field of hematology during the past decade has been that of novel treatment approaches. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise, and available health-system resources. While difficult, these decisions require knowledge of current clinical and experimental data in order for the appropriate integration of novel therapeutic agents and strategies into clinical practice. This educational program provides participants with an overview of the most recent advances in the treatment of hematologic malignancies, as well as specific updates and outcomes of ongoing clinical trials, synthesized into a concise learning opportunity by experts in the field. The cutting-edge data these experts will discuss in an interactive format will provide practitioners with the information they need to incorporate new therapeutic strategies into their patient care decisions. As a result, it will lead to improve remission and survival rates for patients with hematologic malignancies and disorders while minimizing adverse events and maintaining or improving patient quality of life.

LEARNING OBJECTIVES

The target audience for this educational initiative is medical oncologists, hematologists, hematologist-oncologists, pathologists, and allied healthcare professionals caring for patients with hematologic malignancies.

ACCREDITATION INFORMATION

PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this educational activity for a maximum
of 2 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. During the period June 9, 2009 through June 8, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test. Participants must view each section in its entirety to receive full credit for this program.

CME CREDIT
Physicians who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Celgene Corporation and
Cephalon Oncology.

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

This presentation was selected by the American Society of Clinical Oncology^®
as an independent educational activity held adjunct to the ASCO Annual Meeting.
This presentation is not sponsored or endorsed by ASCO.

Educational Concepts Group, LLC (ECG) has Declared the Following Financial Relationships:
ECG receives educational grants from pharmaceutical industry and other commercial supporters. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

The following faculty members have declared relevant financial relationships:

Michael Hallek, MD
Grants/Research Support
Mundipharma International Limited, Roche

Honorarium
Roche

Thomas J. Kipps, MD
Grants/Research Support
Abbott Laboratories, Alliance for Cancer Gene Therapy, Biogen Idec, Celgene Corporation,
Cephalon Inc., CLL Global Research Foundation, Genentech BioOncology,
Genmab, Leukemia and Lymphoma Society, Memgem, National Cancer Institute -
National Institutes of Health, Nodality Inc, sanofi-aventis Group

John P. Leonard, MD
Consultant Fees
Biogen Idec, Celgene Corporation, Cephalon, Inc., Genentech BioOncology, GlaxoSmithKline, Immunomedics, Inc., Millennium Pharmaceuticals, Inc., Novartis, Wyeth

Mathias J. Rummel, MD, PhD
Consultant Fees
Amgen, Inc., Mundipharma International Limited

Honorarium
Amgen, Inc., Cephalon, Inc., Mundipharma International Limited, Roche

Julie M. Vose, MD
Grants/Research Support
Allos Therapeutics, Inc., Astellas Pharma, Inc., Biogen Idec, Bristol-Myers Squibb Company,          Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals, Inc., Novartis